EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model

Si-Yang Li, Paul J Converse, Fabrice Betoudji, Jin Lee, Khisimuzi Mdluli, Anna Upton, Nader Fotouhi, Eric L Nuermberger iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.00035-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Si-Yang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Tuberculosis, Nitroimidazoles, Oxazolidinones, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TB Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A regimen comprised of bedaquiline (BDQ, or B), pretomanid, and linezolid (BPaL) is the first oral 6-month regimen approved by the U.S. Food and Drug Administration and recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TuberculosisNitroimidazolesOxazolidinonesTuberculosis, Multidrug-ResistantAnimalsMiceDiarylquinolinesAntitubercular AgentsLinezolid

Stichwörter der Autor:innen

TBAJ-587TBAJ-876TBI-223bedaquilinechemotherapydiarylquinolinelinezolidoxazolidinonepretomanidtuberculosis

Substanzen

DiarylquinolinesAntitubercular AgentspretomanidLinezolidNitroimidazolesOxazolidinones

Autor:innen und Institutionen

  • Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland, USA.
  • TB Alliance, New York, New York, USA.
  • Evotec, Princeton, New Jersey, USA.

ORCID-Profile: Eric L Nuermberger

Förderung

  • TB Alliance

Zitieren

APA

Li, S. Y., Converse, P. J., Betoudji, F., Lee, J., Mdluli, K., Upton, A., Fotouhi, N., & Nuermberger, E. L. (2023). Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00035-23

Vancouver

Li SY, Converse PJ, Betoudji F, Lee J, Mdluli K, Upton A, et al. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00035-23

BibTeX
@article{Li2023,
  author = {Li, Si-Yang and Converse, Paul J and Betoudji, Fabrice and Lee, Jin and Mdluli, Khisimuzi and Upton, Anna and Fotouhi, Nader and Nuermberger, Eric L},
  title = {Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00035-23}
}
Kostenlos starten →